Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jenna Rychert is active.

Publication


Featured researches published by Jenna Rychert.


PLOS Pathogens | 2012

Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection

Matthew R. Henn; Christian L. Boutwell; Patrick Charlebois; Niall J. Lennon; Karen A. Power; Alexander R. Macalalad; Aaron M. Berlin; Christine M. Malboeuf; Elizabeth Ryan; Sante Gnerre; Michael C. Zody; Rachel L. Erlich; Lisa Green; Andrew Berical; Yaoyu Wang; Monica Casali; Hendrik Streeck; Allyson K. Bloom; Tim Dudek; Damien C. Tully; Ruchi M. Newman; Karen L. Axten; Adrianne D. Gladden; Laura Battis; Michael Kemper; Qiandong Zeng; Terrance Shea; Sharvari Gujja; Carmen Zedlack; Olivier Gasser

Deep sequencing technologies have the potential to transform the study of highly variable viral pathogens by providing a rapid and cost-effective approach to sensitively characterize rapidly evolving viral quasispecies. Here, we report on a high-throughput whole HIV-1 genome deep sequencing platform that combines 454 pyrosequencing with novel assembly and variant detection algorithms. In one subject we combined these genetic data with detailed immunological analyses to comprehensively evaluate viral evolution and immune escape during the acute phase of HIV-1 infection. The majority of early, low frequency mutations represented viral adaptation to host CD8+ T cell responses, evidence of strong immune selection pressure occurring during the early decline from peak viremia. CD8+ T cell responses capable of recognizing these low frequency escape variants coincided with the selection and evolution of more effective secondary HLA-anchor escape mutations. Frequent, and in some cases rapid, reversion of transmitted mutations was also observed across the viral genome. When located within restricted CD8 epitopes these low frequency reverting mutations were sufficient to prime de novo responses to these epitopes, again illustrating the capacity of the immune response to recognize and respond to low frequency variants. More importantly, rapid viral escape from the most immunodominant CD8+ T cell responses coincided with plateauing of the initial viral load decline in this subject, suggestive of a potential link between maintenance of effective, dominant CD8 responses and the degree of early viremia reduction. We conclude that the early control of HIV-1 replication by immunodominant CD8+ T cell responses may be substantially influenced by rapid, low frequency viral adaptations not detected by conventional sequencing approaches, which warrants further investigation. These data support the critical need for vaccine-induced CD8+ T cell responses to target more highly constrained regions of the virus in order to ensure the maintenance of immunodominant CD8 responses and the sustained decline of early viremia.


Science Translational Medicine | 2012

HIV-Specific Cytolytic CD4 T Cell Responses During Acute HIV Infection Predict Disease Outcome

Damien Z. Soghoian; Heiko Jessen; Michael Flanders; Kailan Sierra-Davidson; Sam Cutler; Thomas Pertel; Srinika Ranasinghe; Madelene Lindqvist; Isaiah Davis; Kimberly Lane; Jenna Rychert; Eric S. Rosenberg; Alicja Piechocka-Trocha; Abraham L. Brass; Jason M. Brenchley; Bruce D. Walker; Hendrik Streeck

HIV-specific CD4 T cell responses during acute infection show robust cytolytic activity and correlate with a lower viral set point and better clinical outcome. T Cells Take Center Stage With more than 33 million infected people worldwide, the HIV/AIDS pandemic is the most devastating infectious disease in recent history. The virus infects and kills one of the central players in the immune system—the CD4 T cell. CD4 T cells provide critical helper signals to B lymphocytes, enabling B cells to produce antibodies, and they also aid another key immune cell, CD8 T cells, which kill virally infected cells. However, CD4 T cells specific for HIV are preferentially infected with this deadly virus and therefore are presumed to be unable to help the host immune system combat HIV. Given the importance of CD4 T cell responses in other viral infections, Soghoian et al. sought to revisit the role of HIV-specific CD4 T cells in the control of HIV infection. They followed a group of HIV-positive patients starting almost immediately after the individuals became infected. The patients who were able to better control HIV showed a robust and early expansion of their HIV-specific CD4 T cells compared to those subjects who were not able to control the virus. Surprisingly, these T cells comprised not only classical CD4 helper cells but also cytolytic “killer” CD4 T cells. Indeed, these CD4 T cells were able to kill HIV-infected cells directly, suggesting that they are involved in the control of HIV. The researchers also made another key observation. At the earliest point during the acute phase of HIV infection, they found that patients who had HIV-specific CD4 T cells containing lots of the death protein granzyme A progressed much more slowly (1 year or more) to full-blown disease than did those patients with T cells containing much less granzyme A. The quality of T cell response in acute HIV infection was able to predict better or worse disease outcomes later on. The unexpected expansion of CD4 T cells with the ability to directly kill HIV-infected cells observed in this study not only demonstrates the key role that cytolytic CD4 T cells play during HIV infection but also sheds new light on the general immunobiology of these cells and raises questions about their roles in other viral infections. Early immunological events during acute HIV infection are thought to fundamentally influence long-term disease outcome. Whereas the contribution of HIV-specific CD8 T cell responses to early viral control is well established, the role of HIV-specific CD4 T cell responses in the control of viral replication after acute infection is unknown. A growing body of evidence suggests that CD4 T cells—besides their helper function—have the capacity to directly recognize and kill virally infected cells. In a longitudinal study of a cohort of individuals acutely infected with HIV, we observed that subjects able to spontaneously control HIV replication in the absence of antiretroviral therapy showed a significant expansion of HIV-specific CD4 T cell responses—but not CD8 T cell responses—compared to subjects who progressed to a high viral set point (P = 0.038). Markedly, this expansion occurred before differences in viral load or CD4 T cell count and was characterized by robust cytolytic activity and expression of a distinct profile of perforin and granzymes at the earliest time point. Kaplan-Meier analysis revealed that the emergence of granzyme A+ HIV-specific CD4 T cell responses at baseline was highly predictive of slower disease progression and clinical outcome (average days to CD4 T cell count <350/μl was 575 versus 306, P = 0.001). These data demonstrate that HIV-specific CD4 T cell responses can be used during the earliest phase of HIV infection as an immunological predictor of subsequent viral set point and disease outcome. Moreover, these data suggest that expansion of granzyme A+ HIV-specific cytolytic CD4 T cell responses early during acute HIV infection contributes substantially to the control of viral replication.


Journal of Virology | 2011

HIV-1-Specific Interleukin-21+ CD4+ T Cell Responses Contribute to Durable Viral Control through the Modulation of HIV-Specific CD8+ T Cell Function

Mathieu F. Chevalier; Boris Julg; Augustine Pyo; Michael Flanders; Srinika Ranasinghe; Damien Z. Soghoian; Douglas S. Kwon; Jenna Rychert; Jeffrey Lian; Matthias I. Muller; Sam Cutler; Elizabeth McAndrew; Heiko Jessen; Florencia Pereyra; Eric S. Rosenberg; Marcus Altfeld; Bruce D. Walker; Hendrik Streeck

ABSTRACT Functional defects in cytotoxic CD8+ T cell responses arise in chronic human viral infections, but the mechanisms involved are not well understood. In mice, CD4 cell-mediated interleukin-21 (IL-21) production is necessary for the maintenance of CD8+ T cell function and control of persistent viral infections. To investigate the potential role of IL-21 in a chronic human viral infection, we studied the rare subset of HIV-1 controllers, who are able to spontaneously control HIV-1 replication without treatment. HIV-specific triggering of IL-21 by CD4+ T cells was significantly enriched in these persons (P = 0.0007), while isolated loss of IL-21-secreting CD4+ T cells was characteristic for subjects with persistent viremia and progressive disease. IL-21 responses were mediated by recognition of discrete epitopes largely in the Gag protein, and expansion of IL-21+ CD4+ T cells in acute infection resulted in lower viral set points (P = 0.002). Moreover, IL-21 production by CD4+ T cells of HIV controllers enhanced perforin production by HIV-1-specific CD8+ T cells from chronic progressors even in late stages of disease, and HIV-1-specific effector CD8+ T cells showed an enhanced ability to efficiently inhibit viral replication in vitro after IL-21 binding. These data suggest that HIV-1-specific IL-21+ CD4+ T cell responses might contribute to the control of viral replication in humans and are likely to be of great importance for vaccine design.


Journal of Clinical Microbiology | 2013

Multicenter Evaluation of the Vitek MS Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry System for Identification of Gram-Positive Aerobic Bacteria

Jenna Rychert; Carey-Ann D. Burnham; Maureen Bythrow; Omai B. Garner; Christine C. Ginocchio; Rebecca Jennemann; Michael A. Lewinski; Ryhana Manji; A. Brian Mochon; Gary W. Procop; Sandra S. Richter; Linda Sercia; Lars F. Westblade; Mary Jane Ferraro; John A. Branda

ABSTRACT Matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF) is gaining momentum as a tool for bacterial identification in the clinical microbiology laboratory. Compared with conventional methods, this technology can more readily and conveniently identify a wide range of organisms. Here, we report the findings from a multicenter study to evaluate the Vitek MS v2.0 system (bioMérieux, Inc.) for the identification of aerobic Gram-positive bacteria. A total of 1,146 unique isolates, representing 13 genera and 42 species, were analyzed, and results were compared to those obtained by nucleic acid sequence-based identification as the reference method. For 1,063 of 1,146 isolates (92.8%), the Vitek MS provided a single identification that was accurate to the species level. For an additional 31 isolates (2.7%), multiple possible identifications were provided, all correct at the genus level. Mixed-genus or single-choice incorrect identifications were provided for 18 isolates (1.6%). Although no identification was obtained for 33 isolates (2.9%), there was no specific bacterial species for which the Vitek MS consistently failed to provide identification. In a subset of 463 isolates representing commonly encountered important pathogens, 95% were accurately identified to the species level and there were no misidentifications. Also, in all but one instance, the Vitek MS correctly differentiated Streptococcus pneumoniae from other viridans group streptococci. The findings demonstrate that the Vitek MS system is highly accurate for the identification of Gram-positive aerobic bacteria in the clinical laboratory setting.


Journal of Clinical Microbiology | 2013

Multicenter Study Evaluating the Vitek MS System for Identification of Medically Important Yeasts

Lars F. Westblade; Rebecca Jennemann; John A. Branda; Maureen Bythrow; Mary Jane Ferraro; Omai B. Garner; Christine C. Ginocchio; Michael A. Lewinski; Ryhana Manji; A. Brian Mochon; Gary W. Procop; Sandra S. Richter; Jenna Rychert; Linda Sercia; Carey-Ann D. Burnham

ABSTRACT The optimal management of fungal infections is correlated with timely organism identification. Matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry (MS) is revolutionizing the identification of yeasts isolated from clinical specimens. We present a multicenter study assessing the performance of the Vitek MS system (bioMérieux) in identifying medically important yeasts. A collection of 852 isolates was tested, including 20 Candida species (626 isolates, including 58 C. albicans, 62 C. glabrata, and 53 C. krusei isolates), 35 Cryptococcus neoformans isolates, and 191 other clinically relevant yeast isolates; in total, 31 different species were evaluated. Isolates were directly applied to a target plate, followed by a formic acid overlay. Mass spectra were acquired using the Vitek MS system and were analyzed using the Vitek MS v2.0 database. The gold standard for identification was sequence analysis of the D2 region of the 26S rRNA gene. In total, 823 isolates (96.6%) were identified to the genus level and 819 isolates (96.1%) were identified to the species level. Twenty-four isolates (2.8%) were not identified, and five isolates (0.6%) were misidentified. Misidentified isolates included one isolate of C. albicans (n = 58) identified as Candida dubliniensis, one isolate of Candida parapsilosis (n = 73) identified as Candida pelliculosa, and three isolates of Geotrichum klebahnii (n = 6) identified as Geotrichum candidum. The identification of clinically relevant yeasts using MS is superior to the phenotypic identification systems currently employed in clinical microbiology laboratories.


European Journal of Clinical Microbiology & Infectious Diseases | 2013

Identification of Enterobacteriaceae by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using the VITEK MS system.

Sandra S. Richter; Linda Sercia; John A. Branda; Carey-Ann D. Burnham; Maureen Bythrow; Mary Jane Ferraro; Omai B. Garner; Christine C. Ginocchio; Rebecca Jennemann; Michael A. Lewinski; Ryhana Manji; A. B. Mochon; Jenna Rychert; Lars F. Westblade; Gary W. Procop

This multicenter study evaluated the accuracy of matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry identifications from the VITEK MS system (bioMérieux, Marcy l’Etoile, France) for Enterobacteriaceae typically encountered in the clinical laboratory. Enterobacteriaceae isolates (n = 965) representing 17 genera and 40 species were analyzed on the VITEK MS system (database v2.0), in accordance with the manufacturer’s instructions. Colony growth (≤72 h) was applied directly to the target slide. Matrix solution (α-cyano-4-hydroxycinnamic acid) was added and allowed to dry before mass spectrometry analysis. On the basis of the confidence level, the VITEK MS system provided a species, genus only, or no identification for each isolate. The accuracy of the mass spectrometric identification was compared to 16S rRNA gene sequencing performed at MIDI Labs (Newark, DE). Supplemental phenotypic testing was performed at bioMérieux when necessary. The VITEK MS result agreed with the reference method identification for 96.7 % of the 965 isolates tested, with 83.8 % correct to the species level and 12.8 % limited to a genus-level identification. There was no identification for 1.7 % of the isolates. The VITEK MS system misidentified 7 isolates (0.7 %) as different genera. Three Pantoea agglomerans isolates were misidentified as Enterobacter spp. and single isolates of Enterobacter cancerogenus, Escherichia hermannii, Hafnia alvei, and Raoultella ornithinolytica were misidentified as Klebsiella oxytoca, Citrobacter koseri, Obesumbacterium proteus, and Enterobacter aerogenes, respectively. Eight isolates (0.8 %) were misidentified as a different species in the correct genus. The VITEK MS system provides reliable mass spectrometric identifications for Enterobacteriaceae.


Clinical Microbiology and Infection | 2014

Multi-centre evaluation of mass spectrometric identification of anaerobic bacteria using the VITEK® MS system

Omai B. Garner; A. B. Mochon; John A. Branda; C.-A. Burnham; Maureen Bythrow; Mary Jane Ferraro; Christine C. Ginocchio; Rebecca Jennemann; Ryhana Manji; Gary W. Procop; Sandra S. Richter; Jenna Rychert; Linda Sercia; Lars F. Westblade; Michael A. Lewinski

Accurate and timely identification of anaerobic bacteria is critical to successful treatment. Classic phenotypic methods for identification require long turnaround times and can exhibit poor species level identification. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) is an identification method that can provide rapid identification of anaerobes. We present a multi-centre study assessing the clinical performance of the VITEK(®) MS in the identification of anaerobic bacteria. Five different test sites analysed a collection of 651 unique anaerobic isolates comprising 11 different genera. Multiple species were included for several of the genera. Briefly, anaerobic isolates were applied directly to a well of a target plate. Matrix solution (α-cyano-4-hydroxycinnamic acid) was added and allowed to dry. Mass spectra results were generated with the VITEK(®) MS, and the comparative spectral analysis and organism identification were determined using the VITEK(®) MS database 2.0. Results were confirmed by 16S rRNA gene sequencing. Of the 651 isolates analysed, 91.2% (594/651) exhibited the correct species identification. An additional eight isolates were correctly identified to genus level, raising the rate of identification to 92.5%. Genus-level identification consisted of Actinomyces, Bacteroides and Prevotella species. Fusobacterium nucleatum, Actinomyces neuii and Bacteroides uniformis were notable for an increased percentage of no-identification results compared with the other anaerobes tested. VITEK(®) MS identification of clinically relevant anaerobes is highly accurate and represents a dramatic improvement over other phenotypic methods in accuracy and turnaround time.


AIDS Research and Human Retroviruses | 2010

Detection of HIV gp120 in Plasma During Early HIV Infection Is Associated with Increased Proinflammatory and Immunoregulatory Cytokines

Jenna Rychert; Daryld Strick; Sue Bazner; James Robinson; Eric S. Rosenberg

Events that occur during acute HIV infection likely contribute to the immune dysfunction common in HIV-infected individuals. During this early stage, there is high-level viral replication, loss in CD4(+) T cell number and function, and an up-regulation of proinflammatory and immunoregulatory cytokines. The mechanisms responsible for this are not completely understood. We hypothesize that the HIV envelope glycoprotein, gp120, contributes to immune dysfunction during early HIV infection. Using a cohort of subjects enrolled during acute and early HIV infection, we determined the amount of gp120, TNF-α, IL-6, IL-10, IFN-α, and IFN-γ in plasma at baseline and 6 months. At matched time points, we also measured CD4(+) T cell proliferation, T cell activation, and apoptosis. Plasma from 109 subjects was screened for gp120. Thirty-six subjects (33%) had detectable gp120 (0.5-15.6 ng/ml). Subjects with greater than 1 ng/ml of gp120 at baseline had similar levels at all time points tested, even when viral replication was undetectable due to therapy. Subjects with detectable gp120 had higher levels of plasma IL-6, IL-10, and TNF-α. There was no difference in the level of T cell activation, proliferation, or apoptosis in subjects with gp120 compared to those without. We conclude that persistent expression of gp120 occurs in a subset of individuals. Furthermore, the presence of gp120 is associated with higher levels of plasma IL-6, IL-10, and TNF-α, which may contribute to immune dysfunction during early HIV infection.


Journal of Clinical Microbiology | 2013

Performance of the Vitek MS v2.0 system in distinguishing Streptococcus pneumoniae from nonpneumococcal species of the Streptococcus mitis group.

John A. Branda; Rachelle P. Markham; Cherilyn D. Garner; Jenna Rychert; Mary Jane Ferraro

ABSTRACT The Vitek MS v2.0 matrix-assisted laser desorption ionization–time of flight mass spectrometry system accurately distinguished Streptococcus pneumoniae from nonpneumococcal S. mitis group species. Only 1 of 116 nonpneumococcal isolates (<1%) was misidentified as S. pneumoniae. None of 95 pneumococcal isolates was misidentified. This method provides a rapid, simple means of discriminating among these challenging organisms.


Diagnostic Microbiology and Infectious Disease | 2014

Multicenter validation of the VITEK MS v2.0 MALDI-TOF mass spectrometry system for the identification of fastidious gram-negative bacteria

John A. Branda; Jenna Rychert; Carey-Ann D. Burnham; Maureen Bythrow; Omai B. Garner; Christine C. Ginocchio; Rebecca Jennemann; Michael A. Lewinski; Ryhana Manji; A. Brian Mochon; Gary W. Procop; Sandra S. Richter; Linda Sercia; Lars F. Westblade; Mary Jane Ferraro

The VITEK MS v2.0 MALDI-TOF mass spectrometry systems performance in identifying fastidious gram-negative bacteria was evaluated in a multicenter study. Compared with the reference method (DNA sequencing), the VITEK MS system provided an accurate, species-level identification for 96% of 226 isolates; an additional 1% were accurately identified to the genus level.

Collaboration


Dive into the Jenna Rychert's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Maureen Bythrow

North Shore-LIJ Health System

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Omai B. Garner

University of California

View shared research outputs
Researchain Logo
Decentralizing Knowledge